What is CONMED's stock-based comp?

CONMED (CNMD) reported stock-based comp of $5.5M in Q1 2026.

How has CONMED's stock-based comp changed year-over-year?

CONMED's stock-based comp decreased by 60.3% year-over-year, from $13.86M to $5.5M.

What is the long-term trend for CONMED's stock-based comp?

Over 4 years (2021 to 2025), CONMED's stock-based comp has grown at a 14.7% compound annual growth rate (CAGR), from $16.34M to $28.32M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

CONMED CNMD Stock-Based Comp

Stock-Based Comp at other companies

Johnson & JohnsonJNJ

$300M+4.2%

StrykerSYK

$87M+3.6%

Boston ScientificBSX

$83M+12.2%

VericelVCEL

$11.29M-1.8%

OSI SystemsOSIS

$6.59M-12.9%

Zimmer Biomet HoldingsZBH

$24.2M+23.5%

Other financials

Income statement

See full

Revenue$317.0M-1.3%

Gross profit$183.4M+3.2%

Operating income$25.4M+59.3%

Net income$13.8M+129%

EPS (diluted)$0.45+137%

Balance sheet

See full

Cash & equivalents$35.0M-1.3%

Total debt$862.6M-3.6%

Total equity$1.0B+4.1%

Total assets$2.3B+0.8%

Cash flow

See full

Operating cash flow$13.5M-67.6%

CapEx$2.9M-23.5%

Free cash flow$10.6M-72.0%

Valuation

See full

Market cap$1.04B-35.6%

Enterprise value$1.87B-24.5%

P/E19×+5.4×

P/S0.8×-0.5×

Profitability

See full

Gross margin55.2%-1.0pp

Operating margin8.2%-5.6pp

Net margin4%-5.0pp

FCF margin9%-3.5pp

Returns & leverage

See full

Return on equity5.5%-7.5pp

Debt / equity0.8×-0.1×

Current ratio2.3×0.0×

Where this comes from

Reported directly by CONMED in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: CONMED’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about CONMED's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CONMED's stock-based comp?: CONMED (CNMD) reported stock-based comp of $5.5M in Q1 2026.
How has CONMED's stock-based comp changed year-over-year?: CONMED's stock-based comp decreased by 60.3% year-over-year, from $13.86M to $5.5M.
What is the long-term trend for CONMED's stock-based comp?: Over 4 years (2021 to 2025), CONMED's stock-based comp has grown at a 14.7% compound annual growth rate (CAGR), from $16.34M to $28.32M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.